PharmaShots | Incisive News in 3 Shots

Subscribe Now

Trial

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

November 17, 2021

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021

November 17, 2021

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

November 11, 2021

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis

November 11, 2021

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

October 22, 2021

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

October 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us